Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Ersvaer, Elisabeth ^a   Liseth, Knut ^b   Skavland, Jørn ^a   Gjertsen, Bjørn T ^a,b   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; TRANSCRIPTION FACTOR FOXP3; CD3 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CD25+ T LYMPHOCYTE; CELL REGENERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; FEMALE; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MALE; OBSERVATION; REGENERATION; REGULATORY T LYMPHOCYTE; SEX DIFFERENCE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; CD8+ T LYMPHOCYTE; CELL MOTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEALTH; HELPER CELL; IMMUNOLOGY; LEUKOPENIA; METABOLISM; MIDDLE AGED; PATHOLOGY; SEXUAL DEVELOPMENT; TUMOR CELL CULTURE;

ADULT; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEALTH; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; LEUKOPENIA; MALE; MIDDLE AGED; SEX CHARACTERISTICS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77954321445     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-38     Document Type: Article

References (42)

1. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004, 50:197-222. 10.1016/j.critrevonc.2003.11.002, 15182826.
2. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007, 19:318-30. 10.1016/j.smim.2007.10.004, 2180244, 18023361.
3. Auletta JJ, Lazarus HM. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 2005, 35:835-57. 10.1038/sj.bmt.1704966, 15778723.
4. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006, 20:29-34. 10.1038/sj.leu.2404032, 16281063.
5. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002, 16:1311-8. 10.1038/sj.leu.2402503, 12094255.
6. Parkman R, Cohen G, Carter SL, Weinberg KI, Masinsin B, Guinan E, Kurtzberg J, Wagner JE, Kernan NA. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:919-27. 10.1016/j.bbmt.2006.05.008, 16920557.
7. Kim DH, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB. Rapid helper T-cell recovery above 200 × 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 2006, 37:1119-28. 10.1038/sj.bmt.1705381, 16699530.
8. Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 2007, 220:22-34. 10.1111/j.1600-065X.2007.00567.x, 17979837.
9. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009, 15:3325-32. 10.1158/1078-0432.CCR-08-3010, 19417016.
10. Wang X, Zheng J, Liu J, Yao J, He Y, Li X, Yu J, Yang J, Liu Z, Huang S. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005, 75:468-76. 10.1111/j.1600-0609.2005.00537.x, 16313258.
11. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 2009, 158:199-204. 10.1111/j.1365-2249.2009.04011.x, 19737137.
12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-302. 10.1182/blood-2002-04-1199, 12239137.
13. Ersvaer E, Hampson P, Hatfield K, Ulvestad E, Wendelbo O, Lord JM, Gjertsen BT, Bruserud O. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunol Immunother 2007, 56:913-25. 10.1007/s00262-006-0236-5, 17115221.
14. Bruserud O, Ulvestad E. Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia. J Interferon Cytokine Res 2000, 20:947-54. 10.1089/10799900050198381, 11096451.
15. Bruserud O, Ulvestad E, Berentsen S, Bergheim J, Nesthus I. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation. Scand J Immunol 1998, 47:54-62. 10.1046/j.1365-3083.1998.00254.x, 9467659.
16. Bruserud O, Ulvestad E. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Cell Immunol 2000, 206:36-50. 10.1006/cimm.2000.1725, 11161436.
17. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, Nolan GP. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-28. 10.1016/j.cell.2004.06.028, 15260991.
18. Wendelbo O, Bruserud O. Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay. J Hematother Stem Cell Res 2003, 12:525-35. 10.1089/152581603322448231, 14594509.
19. Bruserud O, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004, 89:391-402.
20. Ersvaer E, Hampson P, Wendelbo O, Lord JM, Gjertsen BT, Bruserud O. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology 2007, 12:199-207. 10.1080/10245330701255163, 17558695.
21. Ersvaer E, Olsnes AM, Bruserud O. The Immunological Dilemma: Cellular Innate and Adaptive Immune Response Versus Human Acute Myeloid Leukemia. Open Hematology Reviews 2007, 1:1-14.
22. Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK, Bunce CM, Lord JM. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005, 106:1362-8. 10.1182/blood-2004-10-4117, 15845901.
23. Schwarzenberger P, Kolls JK. Interleukin 17: an example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis. J Cell Biochem Suppl 2002, 38:88-95. 10.1002/jcb.10054, 12046855.
24. Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK, Darley RL. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007, 21:2495-505. 10.1038/sj.leu.2404961, 17898786.
25. Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud O. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunol Immunother 2006,
26. Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am 1993, 7:47-64.
27. Beran M, Andersson B, Kantarjian H, Keating M, Rios A, McCredie KB, Freireich EJ, Gutterman J. Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia 1987, 1:52-7.
28. Kim H, Sohn HJ, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006, 37:1037-42. 10.1038/sj.bmt.1705373, 16708062.
29. Chen Z, JJ O. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008, 41:87-102. 10.1007/s12026-007-8014-9, 18172584.
30. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007, 13:139-45. 10.1038/nm1551, 17290272.
31. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-8. 10.1038/nature04753, 16648838.
32. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-4. 10.1038/nature04754, 16648837.
33. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector th17 and regulatory T cells. J Clin Immunol 2008, 28:660-70. 10.1007/s10875-008-9239-7, 18810613.
34. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007, 178:6730-3.
35. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui M, Leroy K, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008, 57:772-9. 10.1136/gut.2007.123794, 17965063.
36. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001, 167:1137-40.
37. Sakaguchi S, Takahashi T, Yamazaki S, Kuniyasu Y, Itoh M, Sakaguchi N, Shimizu J. Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity. Microbes Infect 2001, 3:911-8. 10.1016/S1286-4579(01)01452-6, 11564439.
38. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163:5211-8.
39. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110:3192-201. 10.1182/blood-2007-06-094615, 2200901, 17616639.
40. Dannull J, Nair S, Su Z, Boczkowski D, DeBeck C, Yang B, Gilboa E, Vieweg J. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005, 105:3206-13. 10.1182/blood-2004-10-3944, 15618466.
41. Bruserud O, Ersvaer E, Olsnes A, Gjertsen BT. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Curr Cancer Drug Targets 2008, 8:666-675. 10.2174/156800908786733496, 19075589.
42. Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009, 10:509-16. 10.1038/gene.2009.12, 2735332, 19279650.